Dapagliflozin-associated euglycemic diabetic ketoacidosis in 66-year-old with type 2 Diabetes: A clinical case report
1 Department of nephrology, CHU Liege, Belgium.
2 Emergency department, CHU Liege, Belgium.
2 Emergency department, CHU Liege, Belgium.
Case Study
World Journal of Biology Pharmacy and Health Sciences, 2024, 19(03), 194–197.
Article DOI: 10.30574/wjbphs.2024.19.3.0602
Publication history:
Received on 03 June 2024; revised on 04 September 2024; accepted on 06 September 2024
Abstract:
Euglycemic diabetic ketoacidosis (EDKA) is a rare but serious complication of type 2 diabetes, often associated with the use of SGLT2 inhibitors. This case report describes an episode of EDKA in a 66-year-old male with a long history of type 2 diabetes and multiple comorbidities, who developed this complication following the introduction of dapagliflozin. Although his blood glucose levels remained within normal limits, laboratory tests revealed elevated ketonemia and severe metabolic acidosis. The patient was successfully treated with intravenous hydration and insulin therapy, leading to a rapid improvement in his clinical condition. This case underscores the importance of clinical vigilance and patient education for those treated with SGLT2 inhibitors to prevent and effectively manage this potentially life-threatening complication.
Keywords:
Euglycemic diabetic ketoacidosis; Dapagliflozin; SGLT2 inhibitors; Type 2 diabetes; Insulin therapy
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0